Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8<sup>+</sup> T Cell Response in Hepatocellular Carcinoma

Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8<sup>+</sup> T Cell Response in Hepatocellular Carcinoma

Thirty to fifty percent of hepatocellular carcinomas (HCC) display an immune class genetic signature. In this type of tumor, HCC-specific CD8 T cells carry out a key role in HCC control. Those potential reactive HCC-specific CD8 T cells recognize either HCC immunogenic neoantigens or aberrantly expr...

Full description

Bibliographic Details
Main Authors: Julia Peña-Asensio, Henar Calvo, Miguel Torralba, Joaquín Miquel, Eduardo Sanz-de-Villalobos, Juan-Ramón Larrubia
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
hepatocellular carcinoma
immunotherapy
PD-1
PD-L1
immune check-point inhibitor
combination therapy
Online Access:https://www.mdpi.com/2072-6694/13/8/1922

Internet

https://www.mdpi.com/2072-6694/13/8/1922

Similar Items